MAP4K4 and neoplasm: While the results shown here bear solely on cell survival, the demonstrated lack of a confounding effect on tumour cell killing by DOX gives obvious credence to further exploration of MAP4K4 inhibitors in these further aspects of cancer therapeutics, beyond just cardioprotection.